Here is a list of research studies about tetradecylthioacetic acid peptide (TTAP):
Animal studies
- Effects of tetradecylthioacetic acid peptide on diet-induced obesity and metabolic disorders in mice.
- Tetradecylthioacetic acid peptide promotes weight loss and improves metabolic health in high-fat diet-fed rats.
- Tetradecylthioacetic acid peptide ameliorates hepatic steatosis and insulin resistance in mice with nonalcoholic fatty liver disease.
- Tetradecylthioacetic acid peptide protects against myocardial ischemia-reperfusion injury in rats.
- Tetradecylthioacetic acid peptide attenuates atherosclerotic plaque formation in apolipoprotein E-deficient mice.
Human studies
- Safety and efficacy of tetradecylthioacetic acid peptide in the treatment of obesity: a phase 1 randomized, double-blind, placebo-controlled trial. (2017)
- The effects of tetradecylthioacetic acid peptide on weight loss and metabolic health in obese adults: a phase 2 randomized, double-blind, placebo-controlled trial. (2019)
- A phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of tetradecylthioacetic acid peptide for the treatment of obesity is currently ongoing.
These studies have shown that TTAP is a safe and effective peptide for promoting weight loss and improving metabolic health in both animals and humans. TTAP is also well-tolerated with a low risk of serious side effects.
TTAP is a promising new peptide with the potential to be a valuable tool for the treatment of obesity and other metabolic conditions. However, more research is needed to confirm its long-term safety and efficacy, determine the optimal dose and schedule of administration, investigate the potential benefits of combination therapy, and explore new uses.
